Kwun Kuen, Law

Executive Manager
Orient Pharma

​

My professional journey in pharmacy began at Linkou Chang Gung Memorial Hospital, where I spent five years delivering outpatient, inpatient, and medication consultation services. This experience allowed me to develop a broad understanding of pharmacology and clinical applications across various therapeutic areas, and cultivated a keen sensitivity to the real-world medication needs in clinical settings. For two of those years, I was solely responsible for the night shift pharmacy, managing urgent medical situations and honing critical crisis management skills.
 
Driven by a desire to make a broader impact in pharmaceutical innovation, I transitioned to AstraZeneca, where I spent five years navigating both commercial and marketing roles. I started as a sales representative covering internal medicine across multiple hospital channels, and later took on brand marketing responsibilities for cardiovascular products such as lipid-lowering therapies. This expanded my strategic insight into product promotion across different stages of the product life cycle.
 
Subsequently, I spent eight years managing my own community pharmacy, gaining firsthand experience in end-user healthcare and bridging the final mile of the medication delivery journey.
 
In 2017, I returned to the pharmaceutical industry, taking on strategic roles at OrientEuro Pharma and subsequently Orient Pharma, where I led market access planning for 505(b)(2) new drugs. I successfully secured Taiwan’s first-in-market NHI reimbursement pricing for CV/CNS product and developed real-world evidence (RWE) strategies to support post-launch lifecycle extension. By challenging the traditional mindset that defines drugs as either originator or generic, I helped pioneer the positioning and medical adoption of me-better therapies within the healthcare system, enabling the Orient Group to enter a new blue ocean of specialty biotech innovation.​

 

Speech title & Synopsis

Company Profile

Corporate Vision: Becoming Asia’s Leading Specialty Pharma
Orient Pharma is committed to becoming a flagship specialty pharmaceutical company in Asia, with a focus on 505(b)(2) drug development and global market expansion. Guided by the core values of integrity, alignment, and differentiation, the company strives to deliver meaningful value to patients, partners, and employees. With Taiwan as its R&D and manufacturing base, Orient Pharma is building vertically integrated capabilities across research, production, and commercialization, while expanding into the U.S., Southeast Asia, and Australia.
 
Strategic Focus: Market-Driven R&D
Orient Pharma follows a market-driven R&D strategy, where its business development team integrates market insights, competitive intelligence, and epidemiological data to identify high-potential, unmet medical needs. Close collaboration between commercial and R&D teams ensures that new products are clinically relevant and commercially viable.
 
Technology Platforms: Three Innovation Drivers
Orient Pharma leverages three proprietary drug delivery technologies to support the development of 505(b)(2) drugs:
Semi-solid Matrix Release Technology (SMRT)
Multi-Unit Pellet System (MUPS)
Osmotic Controlled Release System (OROS)
 
These platforms support the development of new indications, dosage forms, combinations, and strengths. They also help reduce development timelines and costs while improving drug performance and patient adherence.
 
Commercial Advantages: Efficient Development and Patent Protection
The 505(b)(2) regulatory pathway allows Orient Pharma to leverage existing data to streamline clinical development, shorten time-to-market, and reduce costs. U.S. FDA market exclusivity and robust patent strategies further secure early-stage market advantages and enhance global competitiveness.
 
Management Philosophy: Systematic Operations and Talent Development
Orient Pharma emphasizes structured management, clear accountability, and professional specialization. Through institutionalized talent development, cross-functional collaboration, and a culture of resilience and continuous improvement, the company builds high-performing teams that drive sustainable innovation and growth.